Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib in PVNS/TGCT
NCT01261429Phase 2Completed
- Sponsor
- Centre Léon Bérard
- Start
- Dec 2010
- Primary completion
- Apr 2013
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of nilotinib in tenosynovial giant cell tumor (TGCT), sponsored by Centre Léon Bérard. Primary endpoint: Non progression rate at 12 weeks. Started Dec 2010; status: completed.
02
Drugs
nilotinib
03
Conditions
tenosynovial giant cell tumor (TGCT)
Beyond the preview
Go deeper on NCT01261429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01261429.